Squarepoint
DGX icon

Squarepoint’s Quest Diagnostics DGX Stock Holding History

Squarepoint’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$382K Buy
+1,800
New +$353K ﹤0.01% 3646
2026
Q1 		– Sell
-10,100
Closed -$1.75M – 4395
2025
Q4 		$1.75M Buy
+10,100
New +$1.84M ﹤0.01% 2157
2025
Q3 		– Sell
-2,300
Closed -$413K – 4483
2025
Q2 		$413K Sell
2,300
-43,400
-95% -$7.54M ﹤0.01% 3429
2025
Q1 		$7.73M Sell
45,700
-21,400
-32% -$3.52M 0.01% 1147
2024
Q4 		$10.1M Buy
67,100
+44,700
+200% +$6.95M 0.01% 1140
2024
Q3 		$3.48M Sell
22,400
-12,700
-36% -$1.9M 0.01% 1678
2024
Q2 		$4.8M Sell
35,100
-31,400
-47% -$4.3M 0.01% 1410
2024
Q1 		$8.85M Hold
66,500
– – 0.02% 1076
2023
Q4 		$9.17M Buy
66,500
+27,100
+69% +$3.56M 0.02% 998
2023
Q3 		$4.8M Buy
+39,400
New +$5.25M 0.01% 1207

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Squarepoint's DGX Position: Q2 2026 in Review

Squarepoint reduced its Quest Diagnostics (DGX) stake by 66% in Q2 2026, selling an estimated $44.7M and leaving 117,831 shares worth $25M. The position accounts for 0.03% of the portfolio, ranked #596.

Squarepoint first reported a position in DGX in Q2 2015 and has held it in 38 quarters since. The position peaked at $151M in Q2 2025. 1,107 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Squarepoint held 117,831 shares of Quest Diagnostics worth $25M as of Q2 2026.
  • Squarepoint sold 227,957 Quest Diagnostics shares in Q2 2026, an estimated $44.7M.
  • Quest Diagnostics made up 0.03% of Squarepoint's portfolio in Q2 2026, its #596 holding.
  • Squarepoint first reported a position in Quest Diagnostics in Q2 2015 and has held it in 38 quarters since.
  • Squarepoint's Quest Diagnostics position peaked at $151M in Q2 2025.
  • 1,107 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.